CXCR4 is a chemokine receptor which has been shown to be exploited by various tumors for increased survival, invasion, and homing to target organs. We developed a one step radiosynthesis for labeling the CXCR4-specific antagonist AMD3100 with Cu-64 to produce (64)Cu-AMD3100 with a specific activity of 11.28Ci/ micromol (417GBq/ micromol) at the end of radiosynthesis. Incorporation of Cu(II) ion into AMD3100 did not change its ability to inhibit cellular migration in response to the (only) CXCR4 ligand, SDF-1/CXCL12. (64)Cu-AMD3100 binding affinity to CXCR4 was found to be 62.7 microM. Biodistribution of (64)Cu-AMD3100 showed accumulation in CXCR4-expressing organs and tissues, a renal clearance pathway, and an anomalous specific accumulation in the liver. We conclude that (64)Cu-AMD3100 exhibits promise as a potential PET imaging agent for visualization of CXCR4-positive tumors and metastases and might be used to guide and monitor anti-CXCR4 tumor therapy.
CXCR4 is a chemokine receptor which has been shown to be exploited by various n class="Disease">tumors for increased survival, invasion, and homing to target organs. We developed a one step radiosynthesis for labeling the CXCR4-specific antagonist AMD3100 with Cu-64 to produce (64)Cu-AMD3100 with a specific activity of 11.28Ci/ micromol (417GBq/ micromol) at the end of radiosynthesis. Incorporation of Cu(II) ion into AMD3100 did not change its ability to inhibit cellular migration in response to the (only) CXCR4 ligand, SDF-1/CXCL12. (64)Cu-AMD3100 binding affinity to CXCR4 was found to be 62.7 microM. Biodistribution of (64)Cu-AMD3100 showed accumulation in CXCR4-expressing organs and tissues, a renal clearance pathway, and an anomalous specific accumulation in the liver. We conclude that (64)Cu-AMD3100 exhibits promise as a potential PET imaging agent for visualization of CXCR4-positive tumors and metastases and might be used to guide and monitor anti-CXCR4tumor therapy.
Authors: Jason S Lewis; Judith M Connett; Joel R Garbow; Thomas L Buettner; Yasuhisa Fujibayashi; James W Fleshman; Michael J Welch Journal: Cancer Res Date: 2002-01-15 Impact factor: 12.701
Authors: Xiankai Sun; Melinda Wuest; Gary R Weisman; Edward H Wong; David P Reed; C Andrew Boswell; Ramunas Motekaitis; Arthur E Martell; Michael J Welch; Carolyn J Anderson Journal: J Med Chem Date: 2002-01-17 Impact factor: 7.446
Authors: Preeti Misra; Djamel Lebeche; Hung Ly; Martina Schwarzkopf; George Diaz; Roger J Hajjar; Alison D Schecter; John V Frangioni Journal: J Nucl Med Date: 2008-05-15 Impact factor: 10.057
Authors: Dustin Wayne Demoin; Masahiro Shindo; Hanwen Zhang; Kimberly J Edwards; Inna Serganova; Naga Vara Kishore Pillarsetty; Jason S Lewis; Ronald G Blasberg Journal: Nucl Med Biol Date: 2016-05-14 Impact factor: 2.408
Authors: Ido D Weiss; Orit Jacobson; Dale O Kiesewetter; John P Jacobus; Lawrence P Szajek; Xiaoyuan Chen; Joshua M Farber Journal: Mol Imaging Biol Date: 2012-02 Impact factor: 3.488
Authors: Jesse W Williams; Andrew Elvington; Stoyan Ivanov; Skyler Kessler; Hannah Luehmann; Osamu Baba; Brian T Saunders; Ki-Wook Kim; Michael W Johnson; Clarissa S Craft; Jae-Hoon Choi; Mary G Sorci-Thomas; Bernd H Zinselmeyer; Jonathan R Brestoff; Yongjian Liu; Gwendalyn J Randolph Journal: Circ Res Date: 2017-07-10 Impact factor: 17.367
Authors: Orit Jacobson; Ido D Weiss; Lawrence P Szajek; Gang Niu; Ying Ma; Dale O Kiesewetter; Amnon Peled; Henry S Eden; Joshua M Farber; Xiaoyuan Chen Journal: J Control Release Date: 2011-09-22 Impact factor: 9.776